Eli Lilly and Company (NYSE:LLY) Shares Sold by Paragon Capital Management Ltd

Paragon Capital Management Ltd cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,400 shares of the company’s stock after selling 25 shares during the period. Paragon Capital Management Ltd’s holdings in Eli Lilly and Company were worth $1,089,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter worth $26,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $29,000. Core Wealth Advisors Inc. increased its stake in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.2 %

Eli Lilly and Company stock opened at $883.88 on Monday. The stock has a 50 day moving average of $798.59 and a two-hundred day moving average of $729.89. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $905.45. The stock has a market capitalization of $840.05 billion, a price-to-earnings ratio of 130.17, a PEG ratio of 1.93 and a beta of 0.36. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the business earned $1.62 earnings per share. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Argus upped their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Finally, Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $803.50.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 762,804 shares of company stock valued at $648,109,138 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.